GH Research PLC

GH Research Reports First Quarter 2026 Financial Results and Provides Business Update

GH Research reported a net loss of $19.0 million, or $0.31 per share, for the first quarter of 2026, compared to a loss of $10.8 million, or $0.19 per share, in the same period last year. The company's cash, cash equivalents, and marketable securities decreased to $267.3 million as of March 31, 2026, from $280.7 million as of December 31, 2025. Research and development expenses increased to $12.4 million in Q1 2026 from $7.9 million in Q1 2025, primarily due to higher technical and clinical development costs. General and administrative expenses also increased to $6.4 million in Q1 2026 from $4.9 million in Q1 2025, mainly due to higher professional fees.

•5mo ago

GH Research Announces Pricing of $117.5 Million Underwritten Offering

GH Research priced a $117.5 million underwritten public offering of 6.5 million ordinary shares at $18.00 per share. All shares are being sold by the company, representing a direct capital raise and dilution for existing holders. The offering was initiated by investors including Lynx1 Capital Management, Deep Track Capital, and Foresite Capital. Stifel, Cantor Fitzgerald, and RBC Capital Markets are acting as joint book-running managers. The deal is expected to close on April 30, 2026, subject to customary closing conditions. Proceeds will support the clinical-stage biopharma's development of mebufotenin therapies for treatment-resistant depression.

•6mo ago